Delivery of tumor suppressive miRNA to triple negative breast cancer by targeting cationic liposome

doi:10.3877/cma.j.issn.1674-0793.2017.03.002

Abstract

Abstract:

Objective

To investigate the effect of delivering specific tumor suppressor genes miRNA in triple negative breast cancer (TNBC).

Methods

Film dispersion method was utilized to prepare for the new-pattern hyaluronic acid (HA)-targeted cationic liposome (HA-CLPs). The physicochemical property, such as the representation of the size and zeta-potential of CLPs nanoparticles, was assessed and then the nanoparticles were modified with HA. Confocal and flow cytometry (FCM) was applied to assess targeting capacity, while EdU cell proliferation test and cell wound scratch assay to assess biological effects of HA-CLPs.

Results

Nanoparticles of CLPs were of good dispersibility and shaped as homogeneous form of hollow globe. The average size of CLPs was (180.6±3.4) nm and the average zeta-potential was (43.4±2.8) mV. The average size of HA-targeted nanoparticles and miRNA-loaded HA-targeted nanoparticles was (236.65±6.9) nm and (205.6±2.2) nm. The average zeta-potential of HA-targeted nanoparticles and miRNA-loaded HA-targeted nanoparticles was (29.1±5.4) mV and (11.2±1.1) mV. Confocal and FCM verified the targeting capacity of HA-CLPs to deliver miR-205 around the MDA-MB-231 cell nucleus observably. EdU cell proliferation test and cell wound scratch assay proved that miR-205 and miR-34a sent into MDA-MB-231 cell had the ability to inhibit cell proliferation and migration.

Conclusion

Targeted cationic liposome has specific targeting ability towards MDA-MB-231 cell, and the delivery of miR-205 and miR-34a plays a part in the proliferation and migration inhibition of MDA-MB-231.

Key words: Liposomes, Cations, Hyaluronic acid, Breast neoplasms

Feng Xu, Ting Liu, Yanan Zhao, Sen Lu, Yuanyuan Chen, Yuanyuan Ye, Peifeng Liu, Baosan Han. Delivery of tumor suppressive miRNA to triple negative breast cancer by targeting cationic liposome[J]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(03): 148-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2017.03.002

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2017/V11/I03/148

Figures/Tables 7

References 22

[1]	Kim K, Lee E, Lee J, et al. Clinicopathologic signature of TNBC patients with good prognosis[J]. Cancer Res, 2009, 69(24 Suppl):4065.
[2]	Park Y, Chang M, Lee S, et al. Heterogeneity of triple negative breast cancer (TNBC): TNBC might be divided into two or more subgroups by clinicopathologic findings[J]. Cancer Res, 2010, 69(24 Supplement):6032.
[3]	Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008, 14(5):1368-1376.
[4]	Chacon RD, Costanzo MV. Triple-negative breast cancer[J]. Breast Cancer Res, 2010, 24(2):S3.
[5]	Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need[J]. Oncologist, 2011, 16(Suppl 1):1-11.
[6]	Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options[J]. Chemother Res Pract, 2011:696208.
[7]	Che HL, Bae IH, Lim KS, et al. Novel fabrication of microRNA nanoparticle-coated coronary stent for prevention of post-angioplasty restenosis[J]. Korean Circ J, 2016, 46(1):23-32.
[8]	Hayward SL, Francis DM, Kholmatov P, et al. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer[J]. J Biomed Nanotechnol, 2016, 12(3):554-568.
[9]	Zhong Y, Zhang J, Cheng R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts[J]. J Control Release, 2015, 205:144-154.
[10]	Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer[J]. Biomaterials, 2014, 35(14):4333-4344.
[11]	Pozzi D, Marchini C, Carfarelli F, et al. Transfection efficiency boost of cholesterol-containing lipoplexes[J]. Biochim Biophys Acta, 2012, 1818(9):2335-2343.
[12]	Kong F, Zhou F, Ge L, et al. Mannosylated liposomes for targeted gene delivery[J]. Int J Nanomedicine, 2012, 7:1079-1089.
[13]	Huang Y, Yang T, Zhang W, et al. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo[J]. Int J Nanomedicine, 2014, 9:4581-4595.
[14]	Carmona S, Jorgensen MR, Kolli S, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles[J]. Mol Pharm, 2009, 6(3):706-717.
[15]	Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo[J]. J Control Release, 2010, 149(2):111-116.
[16]	Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome[J]. Biomaterials, 2012, 33(3):916-924.
[17]	Piovan C, Palmieri D, Di Leva G, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer[J]. Mol Oncol, 2012, 6(4):458-472.
[18]	Mackiewicz M, Huppi K, Pitt JJ, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA[J]. Breast cancer Res Treat, 2011, 130(2):663-679.
[19]	Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas[J]. Expert Opin Ther Targets, 2016, 20(6):737-753.
[20]	Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions[J]. Nat Rev Cancer, 2010, 11(1):59-67.
[21]	Lee JS, Anlone M, Pieters E, et al. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes[J]. J Control Release, 2011, 155(2):282-288.
[22]	Sanz V, Coley HM, Silva SR, et al. Protamine and chloroquine enhance gene delivery and expression mediated by RNA-wrapped single walled carbon nanotubes[J]. J Nanosci Nanotechnol, 2012, 12(3):1739-1747.

组别（纳米粒子）	粒径（nm，±s）^a	zeta电位（mV，±s）^a	多分散系数/PDI
CLPs	180.6±3.4	43.4±2.8	0.298
CLPs-miR-205	200.8±2.5	38.1±1.7	0.259
HA-CLPs	236.65±6.9	29.1±5.4	0.35
HA-CLPs-miR-205	205.6±2.2	11.2±1.1	0.314
t₁,t₂,t₃,t₄,t₅,t₆	8.292，12.620，10.691，8.461，2.497，7.426	2.802，4.072，18.544，2.754，3.011，5.426	-
P₁,P₂,P₃,P₄,P₅,P₆	<0.01,<0.01,<0.01,<0.01,>0.05,<0.01	<0.05,<0.05,<0.01,>0.05,<0.01,<0.01	-

组别（纳米粒子）	粒径（nm，±s）^a	zeta电位（mV，±s）^a	多分散系数/PDI
CLPs	180.6±3.4	43.4±2.8	0.298
CLPs-miR-205	200.8±2.5	38.1±1.7	0.259
HA-CLPs	236.65±6.9	29.1±5.4	0.35
HA-CLPs-miR-205	205.6±2.2	11.2±1.1	0.314
t₁,t₂,t₃,t₄,t₅,t₆	8.292，12.620，10.691，8.461，2.497，7.426	2.802，4.072，18.544，2.754，3.011，5.426	-
P₁,P₂,P₃,P₄,P₅,P₆	<0.01,<0.01,<0.01,<0.01,>0.05,<0.01	<0.05,<0.05,<0.01,>0.05,<0.01,<0.01	-

Please choose a citation manager

Content to export